Yana Toropova1, Dmitry Korolev1, Maria Istomina1,2, Galina Shulmeyster1, Alexey Petukhov1,3, Vladimir Mishanin1, Andrey Gorshkov4, Ekaterina Podyacheva1, Kamil Gareev2, Alexei Bagrov5, Oleg Demidov6,7. 1. Almazov National Medical Research Centre, Ministry of Health of the Russian Federation, Saint-Petersburg, 197341, Russian Federation. 2. Saint Petersburg Electrotechnical University "LETI", Saint-Petersburg, 197376, Russian Federation. 3. Personalised Medicine Center, Almazov National Medical Research Centre, Ministry of Health of the Russian Federation, Saint-Petersburg, 197341, Russian Federation. 4. FSBI "Research Institute of Influenza named after A.A. Smorodintsev " Ministry of Health of Russian Federation, Saint-Petersburg, Russian Federation. 5. Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Saint-Petersburg, Russian Federation. 6. Institute of Cytology RAS, Saint-Petersburg, 194064, Russian Federation. 7. INSERM U1231, Faculty of Medicine and Pharmacy, University of Bourgogne-Franche Comté, Dijon, France.
Abstract
BACKGROUND: A promising approach to solve the problem of cytostatic toxicity is targeted drug transport using magnetic nanoparticles (MNPs). PURPOSE: To use calculation to determine the optimal characteristics of the magnetic field for controlling MNPs in the body, and to evaluate the efficiency of magnetically controlled delivery of MNPs in vitro and in vivo to a tumour site in mice. MATERIAL AND METHODS: For the in vitro study, reference MNPs were used, while for in vivo studies, MNPs coated in polylactide including fluorescent indocyanine (MNPs-ICG) were used. The in vivo luminescence intensity study was performed in mice with tumours, with and without of a magnetic field at the sites of interest. The studies were performed on a hydrodynamic stand developed at the Institute of Experimental Medicine of the Almazov National Medical Research Centre of the Ministry of Health of Russia. RESULTS: The use of neodymium magnets facilitated selective accumulation of MNPs. One minute after the administration of MNPs-ICG to mice with a tumour, MNPs-ICG predominantly accumulated in the liver, in the absence and presence of a magnetic field, which indicates its metabolic pathway. The intensity of the fluorescence in the animals' livers did not change over time, although an increase in fluorescence in the tumour was observed in the presence of a magnetic field. CONCLUSION: This type of MNP, used in combination with a magnetic field of calculated strength, can form the basis for the development of magnetically controlled transport of cytostatic drugs into tumour tissue.
BACKGROUND: A promising approach to solve the problem of cytostatic toxicity is targeted drug transport using magnetic nanoparticles (MNPs). PURPOSE: To use calculation to determine the optimal characteristics of the magnetic field for controlling MNPs in the body, and to evaluate the efficiency of magnetically controlled delivery of MNPs in vitro and in vivo to a tumour site in mice. MATERIAL AND METHODS: For the in vitro study, reference MNPs were used, while for in vivo studies, MNPs coated in polylactide including fluorescent indocyanine (MNPs-ICG) were used. The in vivo luminescence intensity study was performed in mice with tumours, with and without of a magnetic field at the sites of interest. The studies were performed on a hydrodynamic stand developed at the Institute of Experimental Medicine of the Almazov National Medical Research Centre of the Ministry of Health of Russia. RESULTS: The use of neodymium magnets facilitated selective accumulation of MNPs. One minute after the administration of MNPs-ICG to mice with a tumour, MNPs-ICG predominantly accumulated in the liver, in the absence and presence of a magnetic field, which indicates its metabolic pathway. The intensity of the fluorescence in the animals' livers did not change over time, although an increase in fluorescence in the tumour was observed in the presence of a magnetic field. CONCLUSION: This type of MNP, used in combination with a magnetic field of calculated strength, can form the basis for the development of magnetically controlled transport of cytostatic drugs into tumour tissue.
Authors: Leonard D Shultz; Bonnie L Lyons; Lisa M Burzenski; Bruce Gott; Xiaohua Chen; Stanley Chaleff; Malak Kotb; Stephen D Gillies; Marie King; Julie Mangada; Dale L Greiner; Rupert Handgretinger Journal: J Immunol Date: 2005-05-15 Impact factor: 5.422
Authors: Yoonjee C Park; Jared B Smith; Tuan Pham; Ragnhild D Whitaker; Christopher A Sucato; James A Hamilton; Elizabeth Bartolak-Suki; Joyce Y Wong Journal: Colloids Surf B Biointerfaces Date: 2014-05-12 Impact factor: 5.268
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Yana G Toropova; Alexey S Golovkin; Anna B Malashicheva; Dmitry V Korolev; Andrey N Gorshkov; Kamil G Gareev; Michael V Afonin; Michael M Galagudza Journal: Int J Nanomedicine Date: 2017-01-13